First Wave BioPharma, Inc. FWBI
Day range unavailable
52-week range unavailable
- Market cap
- 5.99M
- Shares out
- 2.03M
- Forward P/E
- -1.91
- Analysts
- Buy
- Price target
- 36.00 (+1116.2%)
- Earnings date
- May 14, 2024
Key statistics
- Enterprise value
- 72.61M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.37
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -11.52M
- Total cash
- 3.43M
- Total debt
- 6.98M
- Return on equity
- -15.28%
- Short % of float
- 2.30%
- 50-day average
- 3.25
- 200-day average
- 5.14
Analyst view
Consensus: buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
May 14, 2024
Expected May 14, 2024. Consensus EPS estimate -0.32.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 14, 2024 | Mar 1, 2024 | -2.18 | — | — | — |
| Apr 1, 2024 | Dec 1, 2023 | -4.03 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | -12.40 | — | — | — |
| Aug 14, 2023 | Jun 1, 2023 | -20.80 | — | — | — |
| May 12, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| Mar 20, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 18, 2023 | Roth MKM | reit | Buy | Buy |
| Jul 13, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Jun 28, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 12, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| May 14, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 25, 2023 | HC Wainwright & Co. | reit | — | Buy |
About First Wave BioPharma, Inc.
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- firstwavebio.com
News
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
Why SoFi Technologies Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session 
Why Trinity Place Holdings Shares Are Trading Higher By 80%; Here Are 20 Stocks Moving Premarket 
Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session 
Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - 12 Health Care Stocks Moving In Thursday's Pre-Market Session
A Look Into Healthcare Sector Value Stocks - 12 Health Care Stocks Moving In Friday's Intraday Session
- Why Novonix Shares Are Trading Higher By 27%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Your note
Sign in to keep a note on FWBI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BORKOWSKI EDWARD J | Director | Stock Award(Grant) | Jan 1, 2024 | 20,248 |
| CASAMENTO CHARLES J | Director | Stock Award(Grant) | Jan 1, 2024 | 19,937 |
| COELHO MARY THERESA | Director | Stock Award(Grant) | Jan 1, 2024 | 20,237 |
| HOFFMAN DAVID ANDREW | Director | Stock Award(Grant) | Jan 2, 2023 | 90,778 |
| KHOSLA CHAITAN S | Director | Stock Award(Grant) | Mar 12, 2024 | 0 |
| RIDDELL ALASTAIR | Director | Stock Award(Grant) | Jan 1, 2024 | 20,240 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 0.12% | 16,477 | 26.36K | Jun 29, 2023 |
| State Street Corporation | 0.09% | 11,797 | 18.88K | Jun 29, 2023 |
| Acadian Asset Management. LLC | 0.07% | 9,887 | 15.82K | Jun 29, 2023 |
| Tower Research Capital LLC (TRC) | 0.06% | 7,654 | 12.25K | Jun 29, 2023 |
| Osaic Holdings Inc | 0.01% | 1,000 | 1.60K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.12% | 16,477 | 26.36K | Jun 29, 2023 |
| Fidelity Series Total Market Index Fund | 0.01% | 1,127 | 2.10K | May 30, 2023 |